Skip to Main Content

Clinical Research

Clinical trials depend on volunteers from the community.  Samaritan’s clinical research team works with hundreds of patients in the mid-Willamette Valley, connecting them with cutting-edge research through our local principal investigators. The advancement of medicine would not be possible without the continued participation of patients in clinical research.

Samaritan’s clinical research program was established in 2008. Sponsors have included: Pfizer, Boehringer Ingelheim, Spectrum, Celgene, Genentech, Amgen, Genentech, Tragara, Bracco Diagnostic, Eisai, PUMA, Novartis, Incyte, Pharmatech, Medtronic, St. Jude Medical and the National Institutes of Health.

  • National Institute of Health and Federal Drug Administration registration number: IRB00005278.
  • Institutional Organization Number (IORG) is IORG0004448.
  • We are a research affiliate of UCSF for The Alliance for Clinical Trials in Oncology.

For more information, email clinicalresearch@samhealth.org or call 541-768-4352.

 

Current Studies

 

Title More Information

Viral Infection and Respiratory Illness Universal Study [VIRUS]: COVID-19 Registry

Principal Investigator: Brian Delmonaco, MD

For more information on this trial.

Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)

Principal Investigator: Brian Delmonaco, MD

For more information on this trial.

COVID-19 Specimen Biobank

Principal Investigator: Brian Delmonaco, MD

Email clinicalresearch@samhealth.org

Breast

Title More Information

Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (TAILOR RT)

Principal Investigator: Norman Yeh, MD

For more information on this trial.

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Principal Investigator: John Strother, MD

For more information on this trial.


Lung

Title More Information

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Principal Investigator: John Strother, MD

For more information on this trial.

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Principal Investigator: John Strother, MD

For more information on this trial.

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study

Principal Investigator: John Strother, MD

For more information on this trial.

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Principal Investigator: John Strother, MD

For more information on this trial.

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Principal Investigator: John Strother, MD

For more information on this trial.

To learn more about cancer clinical trials available, visit clinicaltrials.gov.

 

Title More Information

Multi-Center, Multi-National, Open Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia

Principal Investigator: Jeff Hsing, MD

For more information on this trial.

 

Title More Information

A Study of Baricitinib in Participants With Rheumatoid Arthritis (RA-BRANCH)

Principal Investigator: Jonathan Jones, MD

For more information on this trial.

For more information about clinical research at Samaritan, contact us at 541-768-4352 or clinicalresearch@samhealth.org.